摘要
目的采用唑来膦酸治疗绝经后乳腺癌患者骨质疏松,分析其疗效及安全性。方法选择绝经后乳腺癌患者作为研究对象,实验组采用唑来膦酸联合来曲唑,对照组仅用来曲唑,测量2组患者治疗前后骨密度,进行VAS疼痛评分,观察并比较2组患者的并发症发生率。结果治疗后实验组患者LI-L4、Ward’s三角、股骨颈的骨密度高于对照组,差异有统计学意义(P<0.05);治疗后2组患者静息痛、前屈后伸痛、翻身痛的VAS评分较治疗前降低,且实验组低于对照组,差异有统计学意义(P<0.05);实验组患者发生发热2例,骨痛1例,总发生率15%,对照组发生率为10%,2组无明显差异,且均经对症治疗后缓解,无不良影响。结论绝经后乳腺癌患者出现骨质疏松,采用唑来膦酸治疗,能够提高骨密度,缓解关节疼痛程度,且不良反应轻微,安全有效。
Objective To analyze the efficacy and safety of Zoledronate for osteoporosis in postmenopausal women with breast cancer. Methods Patients with postmenopausal breast cancer were selected as the research object, the experimental group was treated with Zoledronate, bone mineral density and the incidence of complications of the 2 groups were observed and com- pared. Results Bone density in the experimental group after treatment was significantly higher than that of the control group （ P 〈 0.05 ） ; After treatment, VAS score of rest pain, flexion extension pain, turning pain reduced, and those of the experimental group were lower than those of the control group, the difference was statistically signficant（P 〈 0.05 ） ;Fever occurred in the experimen- tal group were 10% ,pain accounted for 5% ,the total incidence rate was 15% ,in the control group,the incidence rate was 10%, the 2 groups had no significant difference, and they were all eased up after symptomatic treatment with no adverse effects. Conclusion Zoledronate for osteoporosis in postmenopausal patients with breast cancer can improve bone density, ease the pain level, and the adverse reactions are mild, safe and effective.
出处
《实用癌症杂志》
2016年第12期2057-2059,共3页
The Practical Journal of Cancer
关键词
唑来膦酸
绝经后乳腺癌
骨质疏松
Zoledronate
Postmenopausal breast cancer
Osteoporosis
